NextCure, Inc. (NXTC)
$6.08+$0.04 (+0.75%) Today
NextCure Inc is a clinical-stage biopharmaceutical company that is focused on advancing inventive medicines that treat cancer patients that do not respond to, or that have disease progression on, current therapies, through the use of targeted therapies including antibody-drug conjugates. The company's product candidates include NC410 a fusion protein of LAIR-2, a fusion protein that, in combination with pembrolizumab, demonstrated early evidence of clinical activity in colorectal (CRC) and ovarian cancers, and LNCB74, an ADC that is directed to B7-H4, a clinically validated cancer target. The company is also seeking a partner for its other clinical programs such as NC525 and NC318 and its preclinical non-oncology programs NC605, for chronic bone diseases and NC181, for Alzheimer's disease.
| Form 4 transaction type | Transactions | Shares | Total value |
|---|---|---|---|
| Open-market purchase | 13 | 346,761 | $1.71M |
| Open-market sale | 1 | 30,000 | $185K |
| Grant or award | 6 | 15,210 |
Dollar totals are shown for open-market purchases and sales only. Grants, option exercises, gifts and tax withholding are reported by share count because they are not trades at a market price.
17 Form 4 filings on record, the earliest from Jun 20, 2025, newest first.
| Date | Insider | Transaction | Security | Shares | Price | Value |
|---|---|---|---|---|---|---|
| Simcere Zaiming, Inc. | Open-market sale | Common Stock | 30,000 | $6.16 | $185K | |
| ADAR1 Capital Management, LLC - 10% Owner | Open-market purchase | Common Stock | 50,000 | $4.97 | $249K | |
| ADAR1 Capital Management, LLC - 10% Owner | Open-market purchase | Common Stock | 20,000 | $5.00 | $100K | |
| ADAR1 Capital Management, LLC - 10% Owner | Open-market purchase | Common Stock | 20,000 | $5.00 | $100K | |
| ADAR1 Capital Management, LLC - 10% Owner | Open-market purchase | Common Stock | 25,000 | $4.81 | $120K | |
| ADAR1 Capital Management, LLC - 10% Owner | Open-market purchase | Common Stock | 100,000 | $4.90 | $490K | |
| ADAR1 Capital Management, LLC - 10% Owner | Open-market purchase | Common Stock | 77,850 | $4.96 | $386K | |
| ADAR1 Capital Management, LLC - 10% Owner | Open-market purchase | Common Stock | 3,300 | $4.98 | $16K | |
| ADAR1 Capital Management, LLC - 10% Owner | Open-market purchase | Common Stock | 25,000 | $4.98 | $125K | |
| ADAR1 Capital Management, LLC - 10% Owner | Open-market purchase | Common Stock | 8,003 | $4.80 | $38K | |
| ADAR1 Capital Management, LLC - 10% Owner | Open-market purchase | Common Stock | 7,798 | $5.00 | $39K | |
| ADAR1 Capital Management, LLC - 10% Owner | Open-market purchase | Common Stock | 6,400 | $4.95 | $32K | |
| ADAR1 Capital Management, LLC - 10% Owner | Open-market purchase | Common Stock | 1,810 | $5.00 | $9K | |
| ADAR1 Capital Management, LLC - 10% Owner | Open-market purchase | Common Stock | 1,600 | $5.00 | $8K | |
| Elaine V. Jones | Grant or award | Stock Option (Right to Buy) | 2,340 | $0.00 | - | |
| Ellen Feigal | Grant or award | Stock Option (Right to Buy) | 2,340 | $0.00 | - | |
| Anne Elizabeth Borgman | Grant or award | Stock Option (Right to Buy) | 2,340 | $0.00 | - | |
| Stephen W. Webster | Grant or award | Stock Option (Right to Buy) | 2,340 | $0.00 | - | |
| David S. Kabakoff | Grant or award | Stock Option (Right to Buy) | 3,510 | $0.00 | - | |
| John G. Houston | Grant or award | Stock Option (Right to Buy) | 2,340 | $0.00 | - | |
| Kevin G. Shaw - Officer | Grant or award | Employee Stock Option (Right to Buy) | 8,270 | $0.00 | - | |
| Udayan Guha - Officer | Grant or award | Employee Stock Option (Right to Buy) | 14,670 | $0.00 | - | |
| Sourav Kundu - Officer | Grant or award | Employee Stock Option (Right to Buy) | 8,270 | $0.00 | - | |
| Timothy Mayer - Officer | Grant or award | Employee Stock Option (Right to Buy) | 14,670 | $0.00 | - | |
| Michael Richman - Officer | Grant or award | Employee Stock Option (Right to Buy) | 38,190 | $0.00 | - | |
 Steven P. Cobourn - Officer | Grant or award | Employee Stock Option (Right to Buy) | 14,670 | $0.00 | - | |
| David S. Kabakoff | Grant or award | Stock Option (Right to Buy) | 28,050 | $0.00 | - | |
| Elaine V. Jones | Grant or award | Stock Option (Right to Buy) | 18,700 | $0.00 | - |
NextCure, Inc. (NXTC) had 9 insider filings in the last 90 days, with the most recent on 2026-08-12. The full record for NXTC runs to 17 Form 4 filings, the earliest from 2025-06-20. InsiderAlpha tracks every Form 4, Form 144, and 8-K filing in real time.
13 insider purchases of NXTC were filed in the last 90 days, totaling $1.71M.
1 insider sale of NXTC was filed in the last 90 days, totaling $185K.
This page tracks NXTC Form 4 insider transactions, Form 144 sale notices, and 8-K material event disclosures in one timeline. Annual 10-K and quarterly 10-Q reports live on the company's SEC EDGAR page.
Create a free InsiderAlpha account and press Watch on this page to add NXTC to your watchlist. A free account also opens the full scored daily plan with every past day and 3 months of price history. No card is required. Sign up at https://insideralpha.ai/register.
Every Form 4 below links to the original document on SEC EDGAR, so the numbers on this page can be checked against the filing they came from.
Real-time Form 4 alerts, AI-scored daily trade ideas and 10b5-1 plan flags.
